Visiting fellow Erasmus School of Health Policy & Management
- Location
- Burg. Oudlaan 50, Rotterdam
- versteegh@eshpm.eur.nl
More information
‹ Back to overview
Profile
Matthijs Versteegh, PhD (Utrecht, The Netherlands, 1984) is director at the institute for Medical Technology Assessment (iMTA) at Erasmus University of Rotterdam. Matthijs holds an undergraduate in health sciences, and a master (cum laude) in science & technology studies (Maastricht University). He obtained his PhD in health economics on quantifying quality of life for economic evaluations of health from Erasmus University of Rotterdam. After completing his PhD, Matthijs worked for consultancy firm Ecorys (Dutch office) on projects for the European Commission (DG SANCO), the World Health Organisation (in Moldova and Kazakhstan), the World Bank (in India) and large regional variation studies for the Dutch board of Health Insurance (Zorginstituut Nederland). Matthijs is a member of the EuroQoL research foundation and the ‘Jonge Zorgdenktank’.
- Tim Kanters, Jasper Brugts, Olivier Manintveld & Matthijs Versteegh (2021) - Burden of providing informal care for patients with atrial fibrillation - Value in Health, 24 (2), 236-243 - doi: 10.1016/j.jval.2020.09.011
- Mira D. Franken, Anne De Hond, Koen Degeling, Cornelis J.A. Punt, Miriam Koopman, Carin A. Uyl-De Groot, Matthijs M. Versteegh & Martijn G.H. Van Oijen (2020) - Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01481-2
- Valerie Wester, Saskia Groot, Tim Kanters, L Wagner, J Ardesch, Isaac Corro Ramos, MJ Enders-Slegers, M de Ruiter, S le Cessie, Jeanine Los, Greg Papageorgiou, Job Exel & Matthijs Versteegh (2020) - Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE) - Frontiers in Neurology, 11 (3) - doi: 10.3389/fneur.2020.00003 - [link]
- Jasper Brugts, Jesse Veenis, Sumant Radhoe, GCM LInsssen, M Van Gent, CJW Borleffs, J van Ramhorst, P van Pol, R Tukkie, RF Spee, ME Emans, W Kok, V van Halm, L Handoko, SLMA Beeres, MC Post, Eric Boersma, Mattie Lenzen, Olivier Manintveld, H Koffijberg, Pieter Baal, Matthijs Versteegh, TD Smilde, L van Heerebeek, M Rienstra, A Mosterd, PPH Delnoy, FW Asselbergs, HP Brunner-La Rocca & RA de Boer (2020) - A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial. - Netherlands Heart Journal, 28 (1), 16-26 - doi: 10.1007/s12471-019-01341-9
- A. Van Eck Van Der Sluijs, A. A. Bonenkamp, F. W. Dekker, A. C. Abrahams, B. C. Van Jaarsveld, , A. C. Abrahams, B. C. Van Jaarsveld, F. W. Dekker, A. Van Eck Van Der Sluijs, A. A. Bonenkamp, M. C. Verhaar, F. J. Van Ittersum, J. A.J. Bart, M. H. Hemmelder, E. L. Penne, D. G. Struijk, A. Özyilmaz, M. M. Versteegh, L. Hakkaart-Van Roijen, G. A. De Wit, F. T. Boereboom, T. A. Kanters, G. De Graaf, P. Leurs, M. R. Korte, A. M. Schrander, J. Lips, H. P. Krepel, A. Lips, E. J. Hoorn, D. Severs, A. H. Boonstra, R. W. Nette, M. Van Buren, S. Boorsma, J. I. Rotmans, A. M. Van Alphen, E. J.R. Litjens, W. M.T. Janssen, H. S. Brink, S. J. Huisman, M. P. Kooistra, H. Klein, H. H. Vincent, W. J.W. Bos, J. D. Snoep, J. Mulder, A. J. Luik, R. J.L. Klaassen & A. G. Weenink (2019) - Dutch nOcturnal and hoME dialysis Study to Improve Clinical Outcomes (DOMESTICO) - BMC Nephrology, 20 (1) - doi: 10.1186/s12882-019-1526-4
- Ayesha Sajjad, Matthijs Versteegh, Jan Busschbach, J Simon & Leona Roijen (2019) - In Search of a Pan-European Value Set; Application for Eq-5d-3l: The Pecunia Project - Value in Health, 22, S815 - doi: 10.1016/j.jval.2019.09.2204
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-?-blokkers - Nederlands Tijdschrift voor Geneeskunde
- Matthijs Versteegh, Isaac Corro Ramos, Nasuh Buyukkaramikli, Amir Ansaripour, Vivian Reckers & Werner Brouwer (2019) - Severity-Adjusted Probability of Being Cost Effective - Pharmacoeconomics (Print), 37, 1155-1163 - doi: 10.1007/s40273-019-00810-8 - [link]
- Anne Hond, Pieter Bakx & Matthijs Versteegh (2019) - Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population - Social Science & Medicine, 222, 180-187 - doi: 10.1016/j.socscimed.2018.12.028 - [link]
- Maria Gheorghe, Renske Hoefman, Matthijs Versteegh & Job Exel (2019) - Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool - Pharmacoeconomics (Print), 37 (1), 93-103 - doi: 10.1007/s40273-018-0706-6
- Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
- Pieter Baal, Meg Perry-Duxbury, Pieter Bakx, Matthijs Versteegh, Eddy Doorslaer & Werner Brouwer (2018) - A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending - Health Economics, 28 (1), 87-100 - doi: 10.1002/hec.3831
- Werner Brouwer, Pieter Baal, Job Exel & Matthijs Versteegh (2018) - When is it too expensive? Cost-effectiveness thresholds and health care decision-making - European Journal of Health Economics (HEPAC) - doi: 10.1007/s10198-018-1000-4
- Isaac Corro Ramos, Matthijs Versteegh, JM Koenders, GC Linssen, JG Meeder & Maureen Molken (2017) - Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines - Value in Health - doi: 10.1016/j.jval.2017.05.013
- Marcel Jonker, Arthur Attema, Bas Donkers, Elly Stolk & Matthijs Versteegh (2016) - Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment - Health Economics, 26 (12), 1534-1547 - doi: 10.1002/hec.3445
- Matthijs Versteegh, Saskia Knies & Werner Brouwer (2016) - From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare - Pharmacoeconomics (Print), 34 (11), 1071-1074 - doi: 10.1007/s40273-016-0431-y
- Matthijs Versteegh & Werner Brouwer (2016) - Patient and general public preferences for health states: A call to reconsider current guidelines - Social Science & Medicine, 165, 66-74 - doi: 10.1016/j.socscimed.2016.07.043
- Matthijs Versteegh, KM Vermeulen, SMAA Evers, GA de WIt, R Prenger & Elly Stolk (2016) - Dutch Tariff for the Five-Level Version of EQ-5D - Value in Health, 19 (4), 343-352 - doi: 10.1016/j.jval.2016.01.003
- Matthijs Versteegh (2016) - Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis - Pharmacoeconomics (Online), 34, 1133-1144 - doi: 10.1007/s40273-016-0421-0
- Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
- DT Arnold, D Rowen, Matthijs Versteegh, A Morley, CE Hooper & NA Maskell (2015) - Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma - Health and Quality of Life Outcomes, 13 (6) - doi: 10.1186/s12955-014-0196-y
- R Crott, Matthijs Versteegh & Carin Groot (2013) - An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences - Quality of Life Research, 22 (5), 1045-1054 - doi: 10.1007/s11136-012-0220-9.
- BMF Janssen, M (Mark) Oppe, Matthijs Versteegh & Elly Stolk (2013) - Introducing the composite time trade-off: a test of feasibility and face validity - The European Journal Of Health Economics, 14, 5-13 - doi: 10.1007/s10198-013-0503-2
- Arthur Attema & Matthijs Versteegh (2013) - Would you rather be ill now, or later? - Health Economics, 22 (12), 1496-1506 - doi: 10.1002/hec.2894
- Matthijs Versteegh, Arthur Attema, M (Mark) Oppe, N Devlin & Elly Stolk (2013) - Time to tweak the TTO: results from a comparison of alternative specifications of the TTO - European Journal of Health Economics (HEPAC), 14 (1), 43-51 - doi: 10.1007/s10198-013-0507-y
- Arthur Attema, Y Edelaar-Peeters, Matthijs Versteegh & Elly Stolk (2013) - Time trade-off: one methodology, different methods - European Journal of Health Economics (HEPAC), 14 (1), 53-64 - doi: 10.1007/s10198-013-0508-x
- Arthur Attema, Matthijs Versteegh, M (Mark) Oppe, Werner Brouwer & Elly Stolk (2012) - LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS - Health Economics, 22 (4), 376-392 - doi: 10.1002/hec.2804
- Matthijs Versteegh, Annemieke Leunis, JJ Luime, M Boggild, Carin Groot & Elly Stolk (2012) - Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D - Medical Decision Making, 32, 554-568 - doi: 10.1177/0272989X11427761
- Matthijs Versteegh, Annemieke Leunis, Carin Groot & Elly Stolk (2012) - Condition- Specific Preference-Based Measures: Benefit or Burden? - Value in Health, 15, 504-513 - doi: 10.1016/j.jval.2011.12.003
- de Sonneville - Koedoot, Matthijs Versteegh & JS Yaruss (2011) - Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D) - Journal of Fluency Disorders, 36, 222-230 - doi: 10.1016/j.jfludis.2011.03.002
- Matthijs Versteegh, D Rowen, JE Brazier & Elly Stolk (2010) - Mapping onto EQ-5D for patients in poor health - Health and Quality of Life Outcomes, 8 (141), 1-26 - doi: 10.1186/1477-7525-8-141
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-alfaremmers - Nederlands Tijdschrift voor Geneeskunde, 163 - [link]
- M Canoy, Matthijs Versteegh, A L Bredenoord & M Verweij (2018) - De prijs van zorg op een goudschaaltje - Medisch Contact
- M Canoy, A L Bredenoord, M Verweij & Matthijs Versteegh (2018) - Welke patiënten worden de dupe? - NRC Handelsblad (print)
- Matthijs Versteegh (2017) - Vaar niet op deernis voor enkelen bij duur medicijn - NRC Handelsblad (print)
- Matthijs Versteegh (2016) - Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? - Diagnosis uitgevers
- Matthijs Versteegh (2014) - Quality of Life in Economic Evaluations of Health - EUR
- Gimon Graaf, Saskia Groot, Valerie Wester, Heleen Vellekoop, Matthijs Versteegh & M Rutten-van Molken (2019) - WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND - [link] - ZonMw
- Tim Kanters, Jasper Brugts, Olivier Manintveld & Matthijs Versteegh (2021) - Burden of providing informal care for patients with atrial fibrillation - Value in Health, 24 (2), 236-243 - doi: 10.1016/j.jval.2020.09.011
- Mira D. Franken, Anne De Hond, Koen Degeling, Cornelis J.A. Punt, Miriam Koopman, Carin A. Uyl-De Groot, Matthijs M. Versteegh & Martijn G.H. Van Oijen (2020) - Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01481-2
- Valerie Wester, Saskia Groot, Tim Kanters, L Wagner, J Ardesch, Isaac Corro Ramos, MJ Enders-Slegers, M de Ruiter, S le Cessie, Jeanine Los, Greg Papageorgiou, Job Exel & Matthijs Versteegh (2020) - Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE) - Frontiers in Neurology, 11 (3) - doi: 10.3389/fneur.2020.00003 - [link]
- Jasper Brugts, Jesse Veenis, Sumant Radhoe, GCM LInsssen, M Van Gent, CJW Borleffs, J van Ramhorst, P van Pol, R Tukkie, RF Spee, ME Emans, W Kok, V van Halm, L Handoko, SLMA Beeres, MC Post, Eric Boersma, Mattie Lenzen, Olivier Manintveld, H Koffijberg, Pieter Baal, Matthijs Versteegh, TD Smilde, L van Heerebeek, M Rienstra, A Mosterd, PPH Delnoy, FW Asselbergs, HP Brunner-La Rocca & RA de Boer (2020) - A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial. - Netherlands Heart Journal, 28 (1), 16-26 - doi: 10.1007/s12471-019-01341-9
- A. Van Eck Van Der Sluijs, A. A. Bonenkamp, F. W. Dekker, A. C. Abrahams, B. C. Van Jaarsveld, , A. C. Abrahams, B. C. Van Jaarsveld, F. W. Dekker, A. Van Eck Van Der Sluijs, A. A. Bonenkamp, M. C. Verhaar, F. J. Van Ittersum, J. A.J. Bart, M. H. Hemmelder, E. L. Penne, D. G. Struijk, A. Özyilmaz, M. M. Versteegh, L. Hakkaart-Van Roijen, G. A. De Wit, F. T. Boereboom, T. A. Kanters, G. De Graaf, P. Leurs, M. R. Korte, A. M. Schrander, J. Lips, H. P. Krepel, A. Lips, E. J. Hoorn, D. Severs, A. H. Boonstra, R. W. Nette, M. Van Buren, S. Boorsma, J. I. Rotmans, A. M. Van Alphen, E. J.R. Litjens, W. M.T. Janssen, H. S. Brink, S. J. Huisman, M. P. Kooistra, H. Klein, H. H. Vincent, W. J.W. Bos, J. D. Snoep, J. Mulder, A. J. Luik, R. J.L. Klaassen & A. G. Weenink (2019) - Dutch nOcturnal and hoME dialysis Study to Improve Clinical Outcomes (DOMESTICO) - BMC Nephrology, 20 (1) - doi: 10.1186/s12882-019-1526-4
- Ayesha Sajjad, Matthijs Versteegh, Jan Busschbach, J Simon & Leona Roijen (2019) - In Search of a Pan-European Value Set; Application for Eq-5d-3l: The Pecunia Project - Value in Health, 22, S815 - doi: 10.1016/j.jval.2019.09.2204
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-?-blokkers - Nederlands Tijdschrift voor Geneeskunde
- Matthijs Versteegh, Isaac Corro Ramos, Nasuh Buyukkaramikli, Amir Ansaripour, Vivian Reckers & Werner Brouwer (2019) - Severity-Adjusted Probability of Being Cost Effective - Pharmacoeconomics (Print), 37, 1155-1163 - doi: 10.1007/s40273-019-00810-8 - [link]
- Anne Hond, Pieter Bakx & Matthijs Versteegh (2019) - Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population - Social Science & Medicine, 222, 180-187 - doi: 10.1016/j.socscimed.2018.12.028 - [link]
- Maria Gheorghe, Renske Hoefman, Matthijs Versteegh & Job Exel (2019) - Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool - Pharmacoeconomics (Print), 37 (1), 93-103 - doi: 10.1007/s40273-018-0706-6
- Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
- Pieter Baal, Meg Perry-Duxbury, Pieter Bakx, Matthijs Versteegh, Eddy Doorslaer & Werner Brouwer (2018) - A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending - Health Economics, 28 (1), 87-100 - doi: 10.1002/hec.3831
- Werner Brouwer, Pieter Baal, Job Exel & Matthijs Versteegh (2018) - When is it too expensive? Cost-effectiveness thresholds and health care decision-making - European Journal of Health Economics (HEPAC) - doi: 10.1007/s10198-018-1000-4
- Isaac Corro Ramos, Matthijs Versteegh, JM Koenders, GC Linssen, JG Meeder & Maureen Molken (2017) - Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines - Value in Health - doi: 10.1016/j.jval.2017.05.013
- Marcel Jonker, Arthur Attema, Bas Donkers, Elly Stolk & Matthijs Versteegh (2016) - Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment - Health Economics, 26 (12), 1534-1547 - doi: 10.1002/hec.3445
- Matthijs Versteegh, Saskia Knies & Werner Brouwer (2016) - From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare - Pharmacoeconomics (Print), 34 (11), 1071-1074 - doi: 10.1007/s40273-016-0431-y
- Matthijs Versteegh & Werner Brouwer (2016) - Patient and general public preferences for health states: A call to reconsider current guidelines - Social Science & Medicine, 165, 66-74 - doi: 10.1016/j.socscimed.2016.07.043
- Matthijs Versteegh, KM Vermeulen, SMAA Evers, GA de WIt, R Prenger & Elly Stolk (2016) - Dutch Tariff for the Five-Level Version of EQ-5D - Value in Health, 19 (4), 343-352 - doi: 10.1016/j.jval.2016.01.003
- Matthijs Versteegh (2016) - Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis - Pharmacoeconomics (Online), 34, 1133-1144 - doi: 10.1007/s40273-016-0421-0
- Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
- DT Arnold, D Rowen, Matthijs Versteegh, A Morley, CE Hooper & NA Maskell (2015) - Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma - Health and Quality of Life Outcomes, 13 (6) - doi: 10.1186/s12955-014-0196-y
- R Crott, Matthijs Versteegh & Carin Groot (2013) - An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences - Quality of Life Research, 22 (5), 1045-1054 - doi: 10.1007/s11136-012-0220-9.
- BMF Janssen, M (Mark) Oppe, Matthijs Versteegh & Elly Stolk (2013) - Introducing the composite time trade-off: a test of feasibility and face validity - The European Journal Of Health Economics, 14, 5-13 - doi: 10.1007/s10198-013-0503-2
- Arthur Attema & Matthijs Versteegh (2013) - Would you rather be ill now, or later? - Health Economics, 22 (12), 1496-1506 - doi: 10.1002/hec.2894
- Matthijs Versteegh, Arthur Attema, M (Mark) Oppe, N Devlin & Elly Stolk (2013) - Time to tweak the TTO: results from a comparison of alternative specifications of the TTO - European Journal of Health Economics (HEPAC), 14 (1), 43-51 - doi: 10.1007/s10198-013-0507-y
- Arthur Attema, Y Edelaar-Peeters, Matthijs Versteegh & Elly Stolk (2013) - Time trade-off: one methodology, different methods - European Journal of Health Economics (HEPAC), 14 (1), 53-64 - doi: 10.1007/s10198-013-0508-x
- Arthur Attema, Matthijs Versteegh, M (Mark) Oppe, Werner Brouwer & Elly Stolk (2012) - LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS - Health Economics, 22 (4), 376-392 - doi: 10.1002/hec.2804
- Matthijs Versteegh, Annemieke Leunis, JJ Luime, M Boggild, Carin Groot & Elly Stolk (2012) - Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D - Medical Decision Making, 32, 554-568 - doi: 10.1177/0272989X11427761
- Matthijs Versteegh, Annemieke Leunis, Carin Groot & Elly Stolk (2012) - Condition- Specific Preference-Based Measures: Benefit or Burden? - Value in Health, 15, 504-513 - doi: 10.1016/j.jval.2011.12.003
- de Sonneville - Koedoot, Matthijs Versteegh & JS Yaruss (2011) - Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D) - Journal of Fluency Disorders, 36, 222-230 - doi: 10.1016/j.jfludis.2011.03.002
- Matthijs Versteegh, D Rowen, JE Brazier & Elly Stolk (2010) - Mapping onto EQ-5D for patients in poor health - Health and Quality of Life Outcomes, 8 (141), 1-26 - doi: 10.1186/1477-7525-8-141
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-alfaremmers - Nederlands Tijdschrift voor Geneeskunde, 163 - [link]
- M Canoy, Matthijs Versteegh, A L Bredenoord & M Verweij (2018) - De prijs van zorg op een goudschaaltje - Medisch Contact
- M Canoy, A L Bredenoord, M Verweij & Matthijs Versteegh (2018) - Welke patiënten worden de dupe? - NRC Handelsblad (print)
- Matthijs Versteegh (2017) - Vaar niet op deernis voor enkelen bij duur medicijn - NRC Handelsblad (print)
- Tim Kanters, Jasper Brugts, Olivier Manintveld & Matthijs Versteegh (2021) - Burden of providing informal care for patients with atrial fibrillation - Value in Health, 24 (2), 236-243 - doi: 10.1016/j.jval.2020.09.011
- Mira D. Franken, Anne De Hond, Koen Degeling, Cornelis J.A. Punt, Miriam Koopman, Carin A. Uyl-De Groot, Matthijs M. Versteegh & Martijn G.H. Van Oijen (2020) - Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01481-2
- Valerie Wester, Saskia Groot, Tim Kanters, L Wagner, J Ardesch, Isaac Corro Ramos, MJ Enders-Slegers, M de Ruiter, S le Cessie, Jeanine Los, Greg Papageorgiou, Job Exel & Matthijs Versteegh (2020) - Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE) - Frontiers in Neurology, 11 (3) - doi: 10.3389/fneur.2020.00003 - [link]
- Jasper Brugts, Jesse Veenis, Sumant Radhoe, GCM LInsssen, M Van Gent, CJW Borleffs, J van Ramhorst, P van Pol, R Tukkie, RF Spee, ME Emans, W Kok, V van Halm, L Handoko, SLMA Beeres, MC Post, Eric Boersma, Mattie Lenzen, Olivier Manintveld, H Koffijberg, Pieter Baal, Matthijs Versteegh, TD Smilde, L van Heerebeek, M Rienstra, A Mosterd, PPH Delnoy, FW Asselbergs, HP Brunner-La Rocca & RA de Boer (2020) - A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial. - Netherlands Heart Journal, 28 (1), 16-26 - doi: 10.1007/s12471-019-01341-9
- A. Van Eck Van Der Sluijs, A. A. Bonenkamp, F. W. Dekker, A. C. Abrahams, B. C. Van Jaarsveld, , A. C. Abrahams, B. C. Van Jaarsveld, F. W. Dekker, A. Van Eck Van Der Sluijs, A. A. Bonenkamp, M. C. Verhaar, F. J. Van Ittersum, J. A.J. Bart, M. H. Hemmelder, E. L. Penne, D. G. Struijk, A. Özyilmaz, M. M. Versteegh, L. Hakkaart-Van Roijen, G. A. De Wit, F. T. Boereboom, T. A. Kanters, G. De Graaf, P. Leurs, M. R. Korte, A. M. Schrander, J. Lips, H. P. Krepel, A. Lips, E. J. Hoorn, D. Severs, A. H. Boonstra, R. W. Nette, M. Van Buren, S. Boorsma, J. I. Rotmans, A. M. Van Alphen, E. J.R. Litjens, W. M.T. Janssen, H. S. Brink, S. J. Huisman, M. P. Kooistra, H. Klein, H. H. Vincent, W. J.W. Bos, J. D. Snoep, J. Mulder, A. J. Luik, R. J.L. Klaassen & A. G. Weenink (2019) - Dutch nOcturnal and hoME dialysis Study to Improve Clinical Outcomes (DOMESTICO) - BMC Nephrology, 20 (1) - doi: 10.1186/s12882-019-1526-4
- Ayesha Sajjad, Matthijs Versteegh, Jan Busschbach, J Simon & Leona Roijen (2019) - In Search of a Pan-European Value Set; Application for Eq-5d-3l: The Pecunia Project - Value in Health, 22, S815 - doi: 10.1016/j.jval.2019.09.2204
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-?-blokkers - Nederlands Tijdschrift voor Geneeskunde
- Matthijs Versteegh, Isaac Corro Ramos, Nasuh Buyukkaramikli, Amir Ansaripour, Vivian Reckers & Werner Brouwer (2019) - Severity-Adjusted Probability of Being Cost Effective - Pharmacoeconomics (Print), 37, 1155-1163 - doi: 10.1007/s40273-019-00810-8 - [link]
- Anne Hond, Pieter Bakx & Matthijs Versteegh (2019) - Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population - Social Science & Medicine, 222, 180-187 - doi: 10.1016/j.socscimed.2018.12.028 - [link]
- Maria Gheorghe, Renske Hoefman, Matthijs Versteegh & Job Exel (2019) - Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool - Pharmacoeconomics (Print), 37 (1), 93-103 - doi: 10.1007/s40273-018-0706-6
- Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
- Pieter Baal, Meg Perry-Duxbury, Pieter Bakx, Matthijs Versteegh, Eddy Doorslaer & Werner Brouwer (2018) - A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending - Health Economics, 28 (1), 87-100 - doi: 10.1002/hec.3831
- Werner Brouwer, Pieter Baal, Job Exel & Matthijs Versteegh (2018) - When is it too expensive? Cost-effectiveness thresholds and health care decision-making - European Journal of Health Economics (HEPAC) - doi: 10.1007/s10198-018-1000-4
- Isaac Corro Ramos, Matthijs Versteegh, JM Koenders, GC Linssen, JG Meeder & Maureen Molken (2017) - Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines - Value in Health - doi: 10.1016/j.jval.2017.05.013
- Marcel Jonker, Arthur Attema, Bas Donkers, Elly Stolk & Matthijs Versteegh (2016) - Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment - Health Economics, 26 (12), 1534-1547 - doi: 10.1002/hec.3445
- Matthijs Versteegh, Saskia Knies & Werner Brouwer (2016) - From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare - Pharmacoeconomics (Print), 34 (11), 1071-1074 - doi: 10.1007/s40273-016-0431-y
- Matthijs Versteegh & Werner Brouwer (2016) - Patient and general public preferences for health states: A call to reconsider current guidelines - Social Science & Medicine, 165, 66-74 - doi: 10.1016/j.socscimed.2016.07.043
- Matthijs Versteegh, KM Vermeulen, SMAA Evers, GA de WIt, R Prenger & Elly Stolk (2016) - Dutch Tariff for the Five-Level Version of EQ-5D - Value in Health, 19 (4), 343-352 - doi: 10.1016/j.jval.2016.01.003
- Matthijs Versteegh (2016) - Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis - Pharmacoeconomics (Online), 34, 1133-1144 - doi: 10.1007/s40273-016-0421-0
- Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
- DT Arnold, D Rowen, Matthijs Versteegh, A Morley, CE Hooper & NA Maskell (2015) - Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma - Health and Quality of Life Outcomes, 13 (6) - doi: 10.1186/s12955-014-0196-y
- R Crott, Matthijs Versteegh & Carin Groot (2013) - An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences - Quality of Life Research, 22 (5), 1045-1054 - doi: 10.1007/s11136-012-0220-9.
- BMF Janssen, M (Mark) Oppe, Matthijs Versteegh & Elly Stolk (2013) - Introducing the composite time trade-off: a test of feasibility and face validity - The European Journal Of Health Economics, 14, 5-13 - doi: 10.1007/s10198-013-0503-2
- Arthur Attema & Matthijs Versteegh (2013) - Would you rather be ill now, or later? - Health Economics, 22 (12), 1496-1506 - doi: 10.1002/hec.2894
- Matthijs Versteegh, Arthur Attema, M (Mark) Oppe, N Devlin & Elly Stolk (2013) - Time to tweak the TTO: results from a comparison of alternative specifications of the TTO - European Journal of Health Economics (HEPAC), 14 (1), 43-51 - doi: 10.1007/s10198-013-0507-y
- Arthur Attema, Y Edelaar-Peeters, Matthijs Versteegh & Elly Stolk (2013) - Time trade-off: one methodology, different methods - European Journal of Health Economics (HEPAC), 14 (1), 53-64 - doi: 10.1007/s10198-013-0508-x
- Arthur Attema, Matthijs Versteegh, M (Mark) Oppe, Werner Brouwer & Elly Stolk (2012) - LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS - Health Economics, 22 (4), 376-392 - doi: 10.1002/hec.2804
- Matthijs Versteegh, Annemieke Leunis, JJ Luime, M Boggild, Carin Groot & Elly Stolk (2012) - Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D - Medical Decision Making, 32, 554-568 - doi: 10.1177/0272989X11427761
- Matthijs Versteegh, Annemieke Leunis, Carin Groot & Elly Stolk (2012) - Condition- Specific Preference-Based Measures: Benefit or Burden? - Value in Health, 15, 504-513 - doi: 10.1016/j.jval.2011.12.003
- de Sonneville - Koedoot, Matthijs Versteegh & JS Yaruss (2011) - Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D) - Journal of Fluency Disorders, 36, 222-230 - doi: 10.1016/j.jfludis.2011.03.002
- Matthijs Versteegh, D Rowen, JE Brazier & Elly Stolk (2010) - Mapping onto EQ-5D for patients in poor health - Health and Quality of Life Outcomes, 8 (141), 1-26 - doi: 10.1186/1477-7525-8-141
- Tim Kanters, Jasper Brugts, Olivier Manintveld & Matthijs Versteegh (2021) - Burden of providing informal care for patients with atrial fibrillation - Value in Health, 24 (2), 236-243 - doi: 10.1016/j.jval.2020.09.011
- Mira D. Franken, Anne De Hond, Koen Degeling, Cornelis J.A. Punt, Miriam Koopman, Carin A. Uyl-De Groot, Matthijs M. Versteegh & Martijn G.H. Van Oijen (2020) - Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01481-2
- Valerie Wester, Saskia Groot, Tim Kanters, L Wagner, J Ardesch, Isaac Corro Ramos, MJ Enders-Slegers, M de Ruiter, S le Cessie, Jeanine Los, Greg Papageorgiou, Job Exel & Matthijs Versteegh (2020) - Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE) - Frontiers in Neurology, 11 (3) - doi: 10.3389/fneur.2020.00003 - [link]
- Jasper Brugts, Jesse Veenis, Sumant Radhoe, GCM LInsssen, M Van Gent, CJW Borleffs, J van Ramhorst, P van Pol, R Tukkie, RF Spee, ME Emans, W Kok, V van Halm, L Handoko, SLMA Beeres, MC Post, Eric Boersma, Mattie Lenzen, Olivier Manintveld, H Koffijberg, Pieter Baal, Matthijs Versteegh, TD Smilde, L van Heerebeek, M Rienstra, A Mosterd, PPH Delnoy, FW Asselbergs, HP Brunner-La Rocca & RA de Boer (2020) - A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial. - Netherlands Heart Journal, 28 (1), 16-26 - doi: 10.1007/s12471-019-01341-9
- A. Van Eck Van Der Sluijs, A. A. Bonenkamp, F. W. Dekker, A. C. Abrahams, B. C. Van Jaarsveld, , A. C. Abrahams, B. C. Van Jaarsveld, F. W. Dekker, A. Van Eck Van Der Sluijs, A. A. Bonenkamp, M. C. Verhaar, F. J. Van Ittersum, J. A.J. Bart, M. H. Hemmelder, E. L. Penne, D. G. Struijk, A. Özyilmaz, M. M. Versteegh, L. Hakkaart-Van Roijen, G. A. De Wit, F. T. Boereboom, T. A. Kanters, G. De Graaf, P. Leurs, M. R. Korte, A. M. Schrander, J. Lips, H. P. Krepel, A. Lips, E. J. Hoorn, D. Severs, A. H. Boonstra, R. W. Nette, M. Van Buren, S. Boorsma, J. I. Rotmans, A. M. Van Alphen, E. J.R. Litjens, W. M.T. Janssen, H. S. Brink, S. J. Huisman, M. P. Kooistra, H. Klein, H. H. Vincent, W. J.W. Bos, J. D. Snoep, J. Mulder, A. J. Luik, R. J.L. Klaassen & A. G. Weenink (2019) - Dutch nOcturnal and hoME dialysis Study to Improve Clinical Outcomes (DOMESTICO) - BMC Nephrology, 20 (1) - doi: 10.1186/s12882-019-1526-4
- Ayesha Sajjad, Matthijs Versteegh, Jan Busschbach, J Simon & Leona Roijen (2019) - In Search of a Pan-European Value Set; Application for Eq-5d-3l: The Pecunia Project - Value in Health, 22, S815 - doi: 10.1016/j.jval.2019.09.2204
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-?-blokkers - Nederlands Tijdschrift voor Geneeskunde
- Matthijs Versteegh, Isaac Corro Ramos, Nasuh Buyukkaramikli, Amir Ansaripour, Vivian Reckers & Werner Brouwer (2019) - Severity-Adjusted Probability of Being Cost Effective - Pharmacoeconomics (Print), 37, 1155-1163 - doi: 10.1007/s40273-019-00810-8 - [link]
- Anne Hond, Pieter Bakx & Matthijs Versteegh (2019) - Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population - Social Science & Medicine, 222, 180-187 - doi: 10.1016/j.socscimed.2018.12.028 - [link]
- Maria Gheorghe, Renske Hoefman, Matthijs Versteegh & Job Exel (2019) - Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool - Pharmacoeconomics (Print), 37 (1), 93-103 - doi: 10.1007/s40273-018-0706-6
- Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
- Pieter Baal, Meg Perry-Duxbury, Pieter Bakx, Matthijs Versteegh, Eddy Doorslaer & Werner Brouwer (2018) - A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending - Health Economics, 28 (1), 87-100 - doi: 10.1002/hec.3831
- Werner Brouwer, Pieter Baal, Job Exel & Matthijs Versteegh (2018) - When is it too expensive? Cost-effectiveness thresholds and health care decision-making - European Journal of Health Economics (HEPAC) - doi: 10.1007/s10198-018-1000-4
- Isaac Corro Ramos, Matthijs Versteegh, JM Koenders, GC Linssen, JG Meeder & Maureen Molken (2017) - Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines - Value in Health - doi: 10.1016/j.jval.2017.05.013
- Marcel Jonker, Arthur Attema, Bas Donkers, Elly Stolk & Matthijs Versteegh (2016) - Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment - Health Economics, 26 (12), 1534-1547 - doi: 10.1002/hec.3445
- Matthijs Versteegh, Saskia Knies & Werner Brouwer (2016) - From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare - Pharmacoeconomics (Print), 34 (11), 1071-1074 - doi: 10.1007/s40273-016-0431-y
- Matthijs Versteegh & Werner Brouwer (2016) - Patient and general public preferences for health states: A call to reconsider current guidelines - Social Science & Medicine, 165, 66-74 - doi: 10.1016/j.socscimed.2016.07.043
- Matthijs Versteegh, KM Vermeulen, SMAA Evers, GA de WIt, R Prenger & Elly Stolk (2016) - Dutch Tariff for the Five-Level Version of EQ-5D - Value in Health, 19 (4), 343-352 - doi: 10.1016/j.jval.2016.01.003
- Matthijs Versteegh (2016) - Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis - Pharmacoeconomics (Online), 34, 1133-1144 - doi: 10.1007/s40273-016-0421-0
- Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
- DT Arnold, D Rowen, Matthijs Versteegh, A Morley, CE Hooper & NA Maskell (2015) - Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma - Health and Quality of Life Outcomes, 13 (6) - doi: 10.1186/s12955-014-0196-y
- R Crott, Matthijs Versteegh & Carin Groot (2013) - An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences - Quality of Life Research, 22 (5), 1045-1054 - doi: 10.1007/s11136-012-0220-9.
- BMF Janssen, M (Mark) Oppe, Matthijs Versteegh & Elly Stolk (2013) - Introducing the composite time trade-off: a test of feasibility and face validity - The European Journal Of Health Economics, 14, 5-13 - doi: 10.1007/s10198-013-0503-2
- Arthur Attema & Matthijs Versteegh (2013) - Would you rather be ill now, or later? - Health Economics, 22 (12), 1496-1506 - doi: 10.1002/hec.2894
- Matthijs Versteegh, Arthur Attema, M (Mark) Oppe, N Devlin & Elly Stolk (2013) - Time to tweak the TTO: results from a comparison of alternative specifications of the TTO - European Journal of Health Economics (HEPAC), 14 (1), 43-51 - doi: 10.1007/s10198-013-0507-y
- Arthur Attema, Y Edelaar-Peeters, Matthijs Versteegh & Elly Stolk (2013) - Time trade-off: one methodology, different methods - European Journal of Health Economics (HEPAC), 14 (1), 53-64 - doi: 10.1007/s10198-013-0508-x
- Arthur Attema, Matthijs Versteegh, M (Mark) Oppe, Werner Brouwer & Elly Stolk (2012) - LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS - Health Economics, 22 (4), 376-392 - doi: 10.1002/hec.2804
- Matthijs Versteegh, Annemieke Leunis, JJ Luime, M Boggild, Carin Groot & Elly Stolk (2012) - Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D - Medical Decision Making, 32, 554-568 - doi: 10.1177/0272989X11427761
- Matthijs Versteegh, Annemieke Leunis, Carin Groot & Elly Stolk (2012) - Condition- Specific Preference-Based Measures: Benefit or Burden? - Value in Health, 15, 504-513 - doi: 10.1016/j.jval.2011.12.003
- de Sonneville - Koedoot, Matthijs Versteegh & JS Yaruss (2011) - Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D) - Journal of Fluency Disorders, 36, 222-230 - doi: 10.1016/j.jfludis.2011.03.002
- Matthijs Versteegh, D Rowen, JE Brazier & Elly Stolk (2010) - Mapping onto EQ-5D for patients in poor health - Health and Quality of Life Outcomes, 8 (141), 1-26 - doi: 10.1186/1477-7525-8-141
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-alfaremmers - Nederlands Tijdschrift voor Geneeskunde, 163 - [link]
- M Canoy, Matthijs Versteegh, A L Bredenoord & M Verweij (2018) - De prijs van zorg op een goudschaaltje - Medisch Contact
- M Canoy, A L Bredenoord, M Verweij & Matthijs Versteegh (2018) - Welke patiënten worden de dupe? - NRC Handelsblad (print)
- Matthijs Versteegh (2017) - Vaar niet op deernis voor enkelen bij duur medicijn - NRC Handelsblad (print)
- Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-alfaremmers - Nederlands Tijdschrift voor Geneeskunde, 163 - [link]
- M Canoy, Matthijs Versteegh, A L Bredenoord & M Verweij (2018) - De prijs van zorg op een goudschaaltje - Medisch Contact
- M Canoy, A L Bredenoord, M Verweij & Matthijs Versteegh (2018) - Welke patiënten worden de dupe? - NRC Handelsblad (print)
- Matthijs Versteegh (2017) - Vaar niet op deernis voor enkelen bij duur medicijn - NRC Handelsblad (print)
- Matthijs Versteegh (2016) - Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? - Diagnosis uitgevers
- Matthijs Versteegh (2016) - Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? - Diagnosis uitgevers
- Matthijs Versteegh (2014) - Quality of Life in Economic Evaluations of Health - EUR
- Matthijs Versteegh (2014) - Quality of Life in Economic Evaluations of Health - EUR
- Gimon Graaf, Saskia Groot, Valerie Wester, Heleen Vellekoop, Matthijs Versteegh & M Rutten-van Molken (2019) - WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND - [link] - ZonMw
- Gimon Graaf, Saskia Groot, Valerie Wester, Heleen Vellekoop, Matthijs Versteegh & M Rutten-van Molken (2019) - WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND - [link] - ZonMw